Acadia Healthcare Co., Inc.
Acadia Healthcare Co., Inc. Q1 FY2025 earnings call
May 13, 2025 · fiscal period ended 2025-03
EPS · actual vs est
Revenue · actual vs est
Summary
Generated 2025-05-13
Management highlights
- Chris Hunter noted first quarter revenue and EBITDA were in line with expectations. - Added 378 new beds in Q1, including 90 to existing facilities and 288 from two new facilities. - Added 7 new comprehensive treatment centers, extending market reach to 170 CTCs across 33 states. - Emphasized commitment to quality and safety, with facilities licensed, accredited, and regular inspections; used data for care quality monitoring. - Labor efforts positively impacting recruitment and retention, with premium pay declining sequentially and year-over-year. - Engaged on policy landscape, highlighting importance of supplemental payment programs for Medicaid populations.
Segment performance
First quarter revenue was $770.5 million, just above the midpoint of the outlook range of $765 million to $775 million. Adjusted EBITDA was $134.2 million, near the high end of the outlook range of $130 million to $235 million. Same facility patient days grew 2.2% in the first quarter, including an unfavorable leap year impact of roughly 110 basis points. Revenue contribution details by product segment weren't explicitly broken down in the transcript.
Guidance
- Reaffirmed full-year revenue and adjusted EBITDA guidance ranges. - Expect to add 801,000 total beds in 2025, and 608-800 beds annually from 2026-2028. - Medicaid supplemental payments expected flat to up $15 million in 2025, inclusive of new Tennessee program once approved. - Startup losses expected $50 million to $55 million for 2025, with ~$15 million in Q2. - Anticipate beginning to comp over headwind from underperforming facilities in Q4 2025.
Risks
- Uncertainty in construction timing, licensing, and ramping of new beds. - Policy changes, including potential Medicaid work requirements that could impact patient access. - Legal expenses related to ongoing DOJ and SEC investigations.
Q&A highlights
Q: How to think about the progression of EBITDA with seasonality and various factors?
A: Heather Dixon explained factors like supplemental payment timing, bed additions, underperforming facilities, and rate moderation impact EBITDA progression.
Q: Thoughts on Medicaid and commercial rates?
A: Chris Hunter said good discussions with payer partners, outlook assumed low single-digit same facility revenue per day growth with conservatism on rates.
Q: Demand environment for behavioral health?
A: Chris Hunter stated consistent increasing demand across lines of business due to focus on higher acuity patients and quality commitment.
Q: Favorability in first quarter performance?
A: Heather Dixon mentioned favorable labor trends and startup losses being a couple million dollars better than expectations.
Q: Return target for new facilities?
A: Heather Dixon said they use return on invested capital, apply disciplined approach, and have checkpoints for projects.
Q: CTC revenues and pricing?
A: Chris Hunter said CTC revenue grew 3.6% year over year, with no specific pricing issues noted.
Q: Impact of Tennessee DPP and cash flow?
A: Heather Dixon discussed Tennessee DPP timing impact and CapEx related cash flow factors.
Q: Specialty revenue decline?
A: Heather Dixon said it's driven by facility closures.
Q: Underperforming facilities update?
A: Chris Hunter said underperforming facilities performed in line with expectations, with plan to comp over headwind in Q4 2025
Key numbers
Reported versus consensus
Earnings calendar feed
| Metric | Reported | Consensus | Delta | Prior year |
|---|---|---|---|---|
| EPS | — | — | — | — |
| Revenue | — | — | — | — |
Transcript
May 13, 2025Full transcript unavailable for redistribution
The structured summary above covers the available call sections. Full transcript text is not included on this page.
Continue exploring
Prior quarters
This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.